Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 96

1.

An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses.

Wang G, Kang X, Chen KS, Jehng T, Jones L, Chen J, Huang XF, Chen SY.

Nat Commun. 2020 Mar 13;11(1):1395. doi: 10.1038/s41467-020-15229-5.

2.

A Novel Anti-PD-L1 Vaccine for Cancer Immunotherapy and Immunoprevention.

Chen J, Liu H, Jehng T, Li Y, Chen Z, Lee KD, Shen HT, Jones L, Huang XF, Chen SY.

Cancers (Basel). 2019 Dec 1;11(12). pii: E1909. doi: 10.3390/cancers11121909.

3.

Effects of PEGylation on capture of dextran-coated magnetic nanoparticles in microcirculation.

Chiu CY, Chung TW, Chen SY, Ma YH.

Int J Nanomedicine. 2019 Jul 3;14:4767-4780. doi: 10.2147/IJN.S204844. eCollection 2019.

4.

Transcriptome and Regulatory Network Analyses of CD19-CAR-T Immunotherapy for B-ALL.

Zhang Q, Hu H, Chen SY, Liu CJ, Hu FF, Yu J, Wu Y, Guo AY.

Genomics Proteomics Bioinformatics. 2019 Apr;17(2):190-200. doi: 10.1016/j.gpb.2018.12.008. Epub 2019 Jun 13.

5.

A safe and potent anti-CD19 CAR T cell therapy.

Ying Z, Huang XF, Xiang X, Liu Y, Kang X, Song Y, Guo X, Liu H, Ding N, Zhang T, Duan P, Lin Y, Zheng W, Wang X, Lin N, Tu M, Xie Y, Zhang C, Liu W, Deng L, Gao S, Ping L, Wang X, Zhou N, Zhang J, Wang Y, Lin S, Mamuti M, Yu X, Fang L, Wang S, Song H, Wang G, Jones L, Zhu J, Chen SY.

Nat Med. 2019 Jun;25(6):947-953. doi: 10.1038/s41591-019-0421-7. Epub 2019 Apr 22.

PMID:
31011207
6.

A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy.

Guram K, Kim SS, Wu V, Sanders PD, Patel S, Schoenberger SP, Cohen EEW, Chen SY, Sharabi AB.

Front Immunol. 2019 Mar 18;10:491. doi: 10.3389/fimmu.2019.00491. eCollection 2019. Review.

7.

A novel NF1 frame-shift mutation c.703_704delTA in a Chinese pedigree with neurofibromatosis type 1.

Chen J, Guo B, Ren M, Lin H, Zhang X, Chen SY, Yu XT, Xu ZP.

Int J Ophthalmol. 2018 Sep 18;11(9):1562-1565. doi: 10.18240/ijo.2018.09.22. eCollection 2018.

8.

Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients.

Yang YC, Wang D, Jin L, Yao HW, Zhang JH, Wang J, Zhao XM, Shen CY, Chen W, Wang XL, Shi R, Chen SY, Zhang ZT.

Biosci Rep. 2018 Jul 31;38(4). pii: BSR20180322. doi: 10.1042/BSR20180322. Print 2018 Aug 31.

9.

MYSM1 Is Essential for Maintaining Hematopoietic Stem Cell (HSC) Quiescence and Survival.

Huo Y, Li BY, Lin ZF, Wang W, Jiang XX, Chen X, Xi WJ, Yang AG, Chen SY, Wang T.

Med Sci Monit. 2018 Apr 25;24:2541-2549.

10.

Efficacy of intracellular immune checkpoint-silenced DC vaccine.

Wang D, Huang XF, Hong B, Song XT, Hu L, Jiang M, Zhang B, Ning H, Li Y, Xu C, Lou X, Li B, Yu Z, Hu J, Chen J, Yang F, Gao H, Ding G, Liao L, Rollins L, Jones L, Chen SY, Chen H.

JCI Insight. 2018 Feb 8;3(3). pii: 98368. doi: 10.1172/jci.insight.98368. eCollection 2018 Feb 8.

11.

A Metal-Polyphenol Network Coated Nanotheranostic System for Metastatic Tumor Treatments.

Fan JX, Zheng DW, Mei WW, Chen S, Chen SY, Cheng SX, Zhang XZ.

Small. 2017 Dec;13(48). doi: 10.1002/smll.201702714. Epub 2017 Nov 10.

PMID:
29125688
12.

Circulating tumor DNA detection in lung cancer patients before and after surgery.

Guo N, Lou F, Ma Y, Li J, Yang B, Chen W, Ye H, Zhang JB, Zhao MY, Wu WJ, Shi R, Jones L, Chen KS, Huang XF, Chen SY, Liu Y.

Sci Rep. 2016 Sep 19;6:33519. doi: 10.1038/srep33519.

13.

MYSM1/miR-150/FLT3 inhibits B1a cell proliferation.

Jiang XX, Liu Y, Li H, Gao Y, Mu R, Guo J, Zhang J, Yang YM, Xiao F, Liu B, Wang C, Shen B, Chen SY, Li Z, Yang G.

Oncotarget. 2016 Oct 18;7(42):68086-68096. doi: 10.18632/oncotarget.11738.

14.

Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing.

Chen KZ, Lou F, Yang F, Zhang JB, Ye H, Chen W, Guan T, Zhao MY, Su XX, Shi R, Jones L, Huang XF, Chen SY, Wang J.

Sci Rep. 2016 Aug 24;6:31985. doi: 10.1038/srep31985.

15.

IκB Kinase ε Is an NFATc1 Kinase that Inhibits T Cell Immune Response.

Zhang J, Feng H, Zhao J, Feldman ER, Chen SY, Yuan W, Huang C, Akbari O, Tibbetts SA, Feng P.

Cell Rep. 2016 Jul 12;16(2):405-418. doi: 10.1016/j.celrep.2016.05.083. Epub 2016 Jun 23.

16.

TP53, PIK3CA, FBXW7 and KRAS Mutations in Esophageal Cancer Identified by Targeted Sequencing.

Zheng H, Wang Y, Tang C, Jones L, Ye H, Zhang G, Cao W, Li J, Liu L, Liu Z, Zhang C, Lou F, Liu Z, Li Y, Shi Z, Zhang J, Zhang D, Sun H, Dong H, Dong Z, Guo B, Yan HE, Lu Q, Huang X, Chen SY.

Cancer Genomics Proteomics. 2016 May-Jun;13(3):231-8.

PMID:
27107065
17.

Deubiquitinase MYSM1 Is Essential for Normal Bone Formation and Mesenchymal Stem Cell Differentiation.

Li P, Yang YM, Sanchez S, Cui DC, Dang RJ, Wang XY, Lin QX, Wang Y, Wang C, Chen DF, Chen SY, Jiang XX, Wen N.

Sci Rep. 2016 Feb 26;6:22211. doi: 10.1038/srep22211.

18.

Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients.

Xu S, Lou F, Wu Y, Sun DQ, Zhang JB, Chen W, Ye H, Liu JH, Wei S, Zhao MY, Wu WJ, Su XX, Shi R, Jones L, Huang XF, Chen SY, Chen J.

Cancer Lett. 2016 Jan 28;370(2):324-31. doi: 10.1016/j.canlet.2015.11.005. Epub 2015 Nov 12.

PMID:
26582655
19.

Epigenetic Regulation of Antibody Responses by the Histone H2A Deubiquitinase MYSM1.

Jiang XX, Chou Y, Jones L, Wang T, Sanchez S, Huang XF, Zhang L, Wang C, Chen SY.

Sci Rep. 2015 Sep 8;5:13755. doi: 10.1038/srep13755.

20.

Identification of Genetic Mutations in Human Lung Cancer by Targeted Sequencing.

Feng H, Wang X, Zhang Z, Tang C, Ye H, Jones L, Lou F, Zhang D, Jiang S, Sun H, Dong H, Zhang G, Liu Z, Dong Z, Guo B, Yan H, Yan C, Wang L, Su Z, Li Y, Nandakumar V, Huang XF, Chen SY, Liu D.

Cancer Inform. 2015 Jun 29;14:83-93. doi: 10.4137/CIN.S22941. eCollection 2015.

Supplemental Content

Loading ...
Support Center